ruxolitinib


( Last Updated : September 22, 2021)
Generic Name:
ruxolitinib
Project Status:
Active
Therapeutic Area:
Graft versus host disease
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Jakavi
Project Line:
Reimbursement Review
Project Number:
SR0706-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of chronic graft-versus-host disease in patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of chronic graft-versus-host disease in patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open 12-Jul-21
Call for patient/clinician input closed 03-Sep-21
Clarification:

- Patient input submission received from LC, LLSC, CLL Canada, Myeloma Canada, AAMAC, CMPNRF, CML Network, and CTTC

Submission received 10-Aug-21
Submission accepted 26-Aug-21
Clarification:

- Submission was not accepted for review on 24 Aug 2021

Review initiated 27-Aug-21
Draft CADTH review report(s) provided to sponsor for comment 24-Nov-21
Deadline for sponsors comments 03-Dec-21
CADTH review report(s) and responses to comments provided to sponsor 14-Jan-22
Expert committee meeting (initial) 26-Jan-22
Draft recommendation issued to sponsor February 07, 2022
To
February 09, 2022
Draft recommendation posted for stakeholder feedback  
End of feedback period